Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁶ and Roy Fleischmann⁷, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, ³Aurora Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
Abstract Number: 0426 • ACR Convergence 2022
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Jesus Diaz¹, Guillermo Quiceno², Cathy Lee Ching³ and Adela Castro⁴, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³University of Mississippi Medical Center, Jackson, MS, ⁴Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
Abstract Number: 0789 • ACR Convergence 2022
The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Ingrid Egeland Christensen¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Siri Mjaaland², Grete Birkeland Kro³, Tore K. Kvien¹, David Warren³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Kristin Kaasen Jørgensen⁴, Silje Watterdal Syversen¹, Guro Løvik Goll¹ and Sella Aarrestad Provan¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not well characterized. The aim…
Abstract Number: 0924 • ACR Convergence 2022
Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Aakash V Patel¹, Sarah L Morgan¹, Ralph Green², Maria Danila¹, Tony R Merriman¹, Keith Wanzeck¹, Hamdy Ahmed³ and Angelo Gaffo¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Departments of Pathology and Medicine, University of California Davis at Sacramento, Sacramento, CA, ³University of South Alabama, Mobile, AL
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory arthritis in which the immune system targets synovial joints. Methotrexate, a dihydrofolate reductase and aminoimidazole-4-carboxamide ribonucleotide transformylase inhibitor,…
Abstract Number: 1159 • ACR Convergence 2022
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Ana De Vicente-Delmás¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, David Martínez-López², Alba Herrero-Morant⁴, Eva Galíndez-Agirregoikoa⁵, Nuria Barroso-García⁶, Natalia Palmou-Fontana², Miguel Ángel González-Gay⁷ and Ricardo Blanco⁸, ¹Hospital General Santa María del Puerto, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ⁷Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…
Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 1887 • ACR Convergence 2022
Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
Shivani Rangaswamy¹, Lisa Christopher-Stine², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli³, Brittany Adler², Ellen Eline², William Kelly² and Julie Paik², ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
Abstract Number: 0080 • ACR Convergence 2022
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Juan Ruiz¹, Chi-Fang Wu², Hui Zhao², Sharon Giordano², Suja Rajan³ and Maria Suarez-Almazor⁴, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic and targeted synthetic disease modifying antirheumatic drugs (bDMARD and tsDMARD) are immunosuppressant, and there have been concerns that they might impact tumor immunity…
Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Roy Fleischmann¹, Sebastian Meerwein², Christina Charles-Schoeman³, BERNARD COMBE⁴, Stephen Hall⁵, Nasser Khan⁶, Kyle Carter⁷, Heidi Camp⁸ and Andrea Rubbert-Roth⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁴Montpellier University, Montpellier, France, ⁵Emeritus Research and Monash University, Melbourne, Australia, ⁶AbbVie, Inc., Abbott Park, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Abbvie, Winnetka, IL, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Mengdong He¹, Yvonne Lee², Yinzhu Jin³, Rishi Desai³, Seanna Vine³ and Seoyoung Kim³, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Northwestern University, Chicago, IL, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…
Abstract Number: 1208 • ACR Convergence 2022
Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum
Georgina Nakafero¹, Matthew J. Grainge¹, Tim Card¹, Maarten W Taal¹, Guruprasad P Aithal¹, Christopher P Fox², Christian Mallen³, Danielle van der Windt³, Richard Riley³ and Abhishek Abhishek¹, ¹University of Nottingham, Nottingham, United Kingdom, ²Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, ³Keele University, Keele, United Kingdom
Background/Purpose: Patients established on long-term low-dose weekly methotrexate treatment undergo 3-monthly monitoring blood-tests to facilitate early detection of drug-related adverse events. Regular testing may not…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].